Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Ramanathan

Showing results (271-280 of 302) with videos related to

Pageof 31
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 2, 2016
Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice GuidelineDavendra P S Sohal, Pamela B Mangu, Alok A Khorana, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 10, 2007
Impact of complete response to chemotherapy on overall survival in advanced colorectal cancer: results from Intergroup N9741Grace K Dy, James E Krook, Erin M Green, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 19, 2007
Oxaliplatin pharmacokinetics and pharmacodynamics in adult cancer patients with impaired renal functionChris H Takimoto, Martin A Graham, Graham Lockwood, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2008
Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of liver dysfunction: a study by the National Cancer Institute Organ Dysfunction Working GroupRamesh K Ramanathan, Merrill J Egorin, Chris H M Takimoto, et al.
British Journal of Cancer|December 21, 2019
Phase 2 study of vismodegib, a hedgehog inhibitor, combined with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinomaAna De Jesus-Acosta, Elizabeth A Sugar, Peter J O'Dwyer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 24, 2016
CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancerE G Chiorean, D D Von Hoff, M Reni, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 24, 2018
Metastatic Pancreatic Cancer: ASCO Clinical Practice Guideline UpdateDavendra P S Sohal, Erin B Kennedy, Alok Khorana, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 9, 2012
A multicenter, phase I, dose-escalation study to assess the safety, tolerability, and pharmacokinetics of etirinotecan pegol in patients with refractory solid tumorsGayle S Jameson, John T Hamm, Glen J Weiss, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 16, 2003
Dose-escalating and pharmacological study of oxaliplatin in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group StudyChris H Takimoto, Scot C Remick, Sunil Sharma, et al.
Molecular Cancer Therapeutics|October 22, 2017
Phase I Study of Enavatuzumab, a First-in-Class Humanized Monoclonal Antibody Targeting the TWEAK Receptor, in Patients with Advanced Solid TumorsElaine T Lam, S Gail Eckhardt, Wells Messersmith, et al.
Pageof 31

Showing results (271-280 of 302) with videos related to

Sort By:
Pageof 31
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 2, 2016
Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice GuidelineDavendra P S Sohal, Pamela B Mangu, Alok A Khorana, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 10, 2007
Impact of complete response to chemotherapy on overall survival in advanced colorectal cancer: results from Intergroup N9741Grace K Dy, James E Krook, Erin M Green, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 19, 2007
Oxaliplatin pharmacokinetics and pharmacodynamics in adult cancer patients with impaired renal functionChris H Takimoto, Martin A Graham, Graham Lockwood, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2008
Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of liver dysfunction: a study by the National Cancer Institute Organ Dysfunction Working GroupRamesh K Ramanathan, Merrill J Egorin, Chris H M Takimoto, et al.
British Journal of Cancer|December 21, 2019
Phase 2 study of vismodegib, a hedgehog inhibitor, combined with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinomaAna De Jesus-Acosta, Elizabeth A Sugar, Peter J O'Dwyer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 24, 2016
CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancerE G Chiorean, D D Von Hoff, M Reni, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 24, 2018
Metastatic Pancreatic Cancer: ASCO Clinical Practice Guideline UpdateDavendra P S Sohal, Erin B Kennedy, Alok Khorana, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 9, 2012
A multicenter, phase I, dose-escalation study to assess the safety, tolerability, and pharmacokinetics of etirinotecan pegol in patients with refractory solid tumorsGayle S Jameson, John T Hamm, Glen J Weiss, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 16, 2003
Dose-escalating and pharmacological study of oxaliplatin in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group StudyChris H Takimoto, Scot C Remick, Sunil Sharma, et al.
Molecular Cancer Therapeutics|October 22, 2017
Phase I Study of Enavatuzumab, a First-in-Class Humanized Monoclonal Antibody Targeting the TWEAK Receptor, in Patients with Advanced Solid TumorsElaine T Lam, S Gail Eckhardt, Wells Messersmith, et al.
Pageof 31